Posted on 09/12/2009 in Pharmaceutical Company Product News Novartis has unveiled its intentions to further build upon its oncology portfolio in a bid to strengthen its expertise in this area of therapy.
The firm aims to explore new indications for marketed drugs, progress with 16 new molecular entities and already has two treatments in development and on-schedule as of the end of 2009 - Tasigna and Zometa.
Joe Jimenez, chief executive officer of Novartis' pharmaceuticals division, commented: "The benefits of our sustained research and devlopment investments are reflected in the nearly 30 major regulatory approvals achieved so far in 2009 in the US, Europe, Japan and China."
He added that there are currently 27 projects undergoing late-stage clinical trials and eight further initiatives are awaiting regulatory verdicts.
In other Novartis news, the firm announced last month that the European commission has approved Onbrez Breezhaler (QAB149 or indacaterol) - its once-daily maintenance bronchodilator - for distribution in the EU.Other news stories from 09/12/2009
Read more in the Zenopa News Archive
How this news is generated
|
